Leica Biosystems and Synthon Biopharmaceuticals have partnered to develop a companion diagnostic program for targeted cancer therapies. Leica will develop a fully automated tissue-based companion diagnostic test to run on its BOND™ automated advanced staining systems paired with one of Synthon’s antibody-drug conjugates, to enhance the treatment of solid tumors.
In December 2012, Leica Biosystems teamed up with Galena Biopharma to develop a companion diagnostic for Galena’s NeuVax™ (nelipepimut-S or E75) breast cancer therapeutic. Leica’s Bond Oracle™ Human Epidermal Growth Factor Receptor 2 (HER2) IHC System companion diagnostic was used to support the selection of the patients for the NeuVax Phase III PRESENT study.
